Clinical trials: Platelet Aggregation
Investigation of Platelet Aggregation in Paediatric Patients With Sickle Cell Disease
A Pharmacokinetic (PK) and Pharmacodynamic (PD) Dose-ranging Phase II Study of Ticagrelor in Paediatric Patients With Sickle Cell Disease
The purpose of this Phase II dose-ranging study is to investigate pharmacokinetic (PK) and pharmacodynamic (PD) properties of various doses of ticagrelor followed by 4 weeks of twice-daily treatment in paediatric patients with…
- Trial name
- HESTIA 1 (NCT02214121)
- Testing
- Ticagrelor Dose 1a + Dose 2a, Ticagrelor Dose 1b + Dose 2b
- Where
- 18 sites in United States, Canada and 4 more
- Volunteers
- 46 people
- Sponsor
- AstraZeneca
Stable Coronary Artery Disease
An Asian Study to Assess the Properties and Profile of Ticagrelor in Patients With Stable Coronary Artery Disease
The purpose of the study is to determine the drug characteristics of Ticagrelor, and to determine if 4 weeks treatment will reduce the blood clotting.
- Trial name
- NCT01118325
- Testing
- ticagrelor, clopidogrel
- Where
- 13 sites in Japan, Philippines
- Volunteers
- 146 people
- Sponsor
- AstraZeneca
Sickle Cell Disease
Effect of Ticagrelor vs. Placebo in the Reduction of Vaso-occlusive Crises in Pediatric Patients With Sickle Cell Disease
The purpose of the study is to Evaluate the Effect of Ticagrelor versus Placebo in Reducing the Rate of Vaso-Occlusive Crises in Paediatric Patients with Sickle Cell Disease
- Trial name
- HESTIA3 (NCT03615924)
- Testing
- Ticagrelor
- Where
- 55 sites in United States, Belgium and 14 more
- Volunteers
- 193 people
- Sponsor
- AstraZeneca
Blood Platelets, Clopidogrel
PACT (Platelet Activity After Clopidogrel Termination)
Clopidogrel is a medication that is used to decrease the ability of platelets to form blood clots. The theory has been proposed that, in patients with coronary artery disease or stroke, increased platelet function after…
- Trial name
- PACT (NCT00619073)
- Testing
- clopidogrel + aspirin, Aspirin
- Where
- United States
- Volunteers
- 15 people, healthy volunteers welcome
- Sponsor
- University of Massachusetts, Worcester
Arterial Occlusive Diseases, Coronary Artery Disease
Safety of PZ-128 in Subjects Undergoing Non-Emergent Percutaneous Coronary Intervention
The object of the study is to determine whether different doses of PZ-128, when added to standard medical care in persons undergoing cardiac catheterization/percutaneous coronary intervention, will increase the risk of bleeding.
- Conditions
- Arterial Occlusive Diseases, Coronary Artery Disease, Coronary Disease, Arteriosclerosis
- Trial name
- TRIP-PCI (NCT02561000)
- Testing
- PZ-128
- Where
- 3 sites in United States
- Volunteers
- 100 people
- Sponsor
- Tufts Medical Center
Thrombocytopenia, Myocardial Infarction
Aspirin in Patients With Myocardial Infarction and Thrombocytopenia
Primary Objective: To determine the risk of bleeding from ASA therapy in thrombocytopenic patients who develop Acute Coronary Syndrome (ACS), and assess its effect on the overall morbidity and mortality in these patients as well…
- Trial name
- NCT00501345
- Testing
- Aspirin
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- M.D. Anderson Cancer Center
Wiskott-Aldrich Syndrome, Thrombocytopenia
Thrombocytopenia and Bleeding in Wiskott-Aldrich Syndrome (WAS) Patients
The purpose of this project is to describe the pathophysiology of thrombocytopenia and bleeding in patients with Wiskott-Aldrich Syndrome (WAS) and determine the response to thrombopoietic agents in vitro and in vivo.
- Conditions
- Wiskott-Aldrich Syndrome, Thrombocytopenia, Bleeding
- Trial name
- WAS (NCT00909363)
- Testing
- Promacta, blood drawing in patients with WAS, blood drawing in healthy controls
- Where
- United States
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Weill Medical College of Cornell University
Acute ST Segment Elevation Myocardial Infarction
Platelet Function in Resuscitated Patients
Approx. 65% of resuscitated patients at the intensive care unit for internal medicine are due to myocardial infarction. Almost all patients are initially diagnosed and treated in the cath lab.
- Trial name
- NCT02914795
- Testing
- diagnostic analysis of platelet function
- Where
- Austria
- Volunteers
- 99 people
- Sponsor
- Medical University of Graz
Chronic Kidney Diseases, Heart Attack
Chronic Kidney Disease (CKD) Platelet Study
This study evaluates how aspirin, clopidogrel and ticagrelor work in people with chronic kidney disease (CKD) compared to people with normal kidneys.
- Conditions
- Chronic Kidney Diseases, Heart Attack, Stroke, Ischemic
- Trial name
- NCT03649711
- Testing
- Ticagrelor 90mg, Clopidogrel 75mg, Aspirin 81 mg
- Where
- 2 sites in United States
- Volunteers
- 76 people, healthy volunteers welcome
- Sponsor
- University of Arkansas
HIV
Effects of Raltegravir Based Regimen on Platelet Reactivity, Platelet-monocyte Aggregation and Immune Activation
Cardiovascular disease (CVD) has emerged as a leading cause of morbidity and mortality in HIVinfected individuals. The precise mechanisms underlying this increased cardiovascular risk remain to be elucidated.
- Trial name
- RAPID (NCT02383355)
- Testing
- Raltegravir, Continuation of own regimen
- Volunteers
- 40 people
- Sponsor
- Radboud University Medical Center
Cardiovascular Risk Factor
Consumption of Oral Artificial Sweeteners on Platelet Aggregation and Polyol Excretion
The principal goal for the study is to examine whether ingestion of a beverage containing artificial sweeteners alters in vitro platelet aggregation.
- Trial name
- COSETTE (NCT04731363)
- Testing
- xylitol, 30g, erythritol, 30g, xylitol, 5g
- Where
- United States
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- The Cleveland Clinic
Acute Coronary Syndromes
Study to Learn When Platelets Return to Normal After One Loading Dose of Anti-platelet Drugs in Patients With Symptoms of Acute Coronary Syndromes
To investigate how platelets recover to normal function in subjects who have symptoms of a heart attack or unstable angina and who get a loading dose of prasugrel or clopidogrel for planned coronary angiography.
- Trial name
- NCT01107899
- Testing
- clopidogrel, prasugrel
- Where
- Germany
- Volunteers
- 29 people
- Sponsor
- Eli Lilly and Company
Myocardial Infarction
The Effects of Lovaza® in Acute Myocardial Infarction
This study will explore the safety and effectiveness of adding Lovaza® to the therapeutic program utilized internationally for the treatment of individuals with acute coronary syndromes.
- Trial name
- OmegaMI (NCT01155336)
- Testing
- Lovaza®
- Where
- United States
- Volunteers
- 4 people
- Sponsor
- University of Rochester
Breast Neoplasms
A Study of the Effects of Inhibiting Platelet Function on Circulating Cancer Cells in Breast Cancer Patients
The purpose of this study is to determine the effects of Plavix and aspirin in women with metastatic breast cancer.
- Trial name
- NCT00263211
- Testing
- Plavix, Aspirin
- Where
- United States
- Volunteers
- 48 people
- Sponsor
- Washington University School of Medicine
Platelet Aggregation Inhibitors, Coronary Heart Disease
Determining Genetic Role in Treatment Response to Anti-Platelet Interventions (The PAPI Study)
One of the most common ways for preventing coronary heart disease (CHD) is to take aspirin or clopidogrel. However, studies have shown that not all people respond to these medications.
- Trial name
- NCT00799396
- Testing
- Clopidogrel, Aspirin
- Where
- United States
- Volunteers
- 682 people, healthy volunteers welcome
- Sponsor
- University of Maryland, Baltimore
Platelet Aggregation, Platelet Transcriptome
Pharmacogenomics of Antiplatelet Response - I
This clinical trial is examining the role of genetic polymorphism on the effect of clopidogrel (with or without aspirin) on platelet response in persons at high-risk for myocardial infarction or stroke due to family history of…
- Conditions
- Platelet Aggregation, Platelet Transcriptome, Coronary Artery Disease
- Trial name
- PARes-I (NCT01815008)
- Testing
- Clopidogrel, Aspirin
- Where
- United States
- Volunteers
- 19 people
- Sponsor
- Johns Hopkins University
Coronary Artery Disease
Prasugrel Re-load Strategies
A higher degree of platelet inhibition remains the goal of peri-interventional and long-term anti-thrombotic therapy in patients with coronary artery disease.
- Trial name
- NCT01201772
- Testing
- Prasugrel
- Where
- United States
- Volunteers
- 65 people
- Sponsor
- University of Florida
Bleeding
Platelet Inhibition and Bleeding in Patients Undergoing Emergent Cardiac Surgery
The aim of the study is to evaluate if there is an association between platelet inhibition and surgery-related bleeding in patients undergoing emergent cardiac surgery during dual antiplatelet therapy.
- Trial name
- NCT01468597
- Where
- Austria
- Volunteers
- 167 people
- Sponsor
- Medical University of Graz
Cardiovascular Diseases, Acute Coronary Syndrome
Pharmacogenomics of Anti-platelet Intervention-2 (PAPI-2) Study
It is standard treatment to take anti-platelet medication after cardiac catheterization and stent placement to help prevent the formation of blood clots that may cause heart attack or stroke.
- Trial name
- PAPI-2 (NCT01452152)
- Testing
- clopidogrel, prasugrel
- Where
- 5 sites in United States
- Volunteers
- 9 people
- Sponsor
- University of Maryland, Baltimore
Platelet Aggregation, Spontaneous, Migraine With Aura
pLatelEts And MigRaine iN patEnt foRamen Ovale
Migraine is a common, chronic neurovascular disorder characterized by attacks of severe headache, autonomic nervous system dysfunction and, in some patients, aura, and disabling neurological symptoms.
- Conditions
- Platelet Aggregation, Spontaneous, Migraine With Aura, Patent Foramen Ovale
- Trial name
- LEARNER (NCT03521193)
- Testing
- patent foramen ovale closure
- Where
- Italy
- Volunteers
- 90 people
- Sponsor
- Centro Cardiologico Monzino